By Jason Derry —

Roche Holding AG has
announced an agreement with Synosis Therapeutics in which
Synosis will have rights to five drug candidates that Roche is no longer
developing.  Four of the drugs are in
Phase I clinical trials.  According to
the Press Release, the drugs relate to schizophrenia, cognitive disorders,
Parkinson's Disease, drug dependency, and pain.

Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.